$4.23
0.051.20%
At Close: -
$4.23
00.00%
After Hours: 4:48 PM EDT
15 minutes delayed
Zentalis Pharma
ZNTLNASDAQ
want to know what
the Bulls & Bears Say?
Zentalis Pharma (NASDAQ:ZNTL) Stock, Analyst Ratings, Price Targets, Forecasts
Zentalis Pharmaceuticals Inc has a consensus price target of $19.73 based on the ratings of 56 analysis. The 3 most-recent analyst ratings were released by UBS, Wells Fargo, and Stifel on June 20, 2024, June 18, 2024, and June 18, 2024, respectively. With an average price target of $8 between UBS, Wells Fargo, and Stifel, there's an implied 89.13% upside for Zentalis Pharmaceuticals Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
UBS
Wells Fargo
Stifel
HC Wainwright & Co.
Oppenheimer
1calculated from analyst ratings
Analyst Ratings for Zentalis Pharma
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/20/2024 | Buy Now | 18.2% | UBS | Eliana Merle | $28 → $5 | Downgrade | Buy → Neutral | Get Alert |
| 06/18/2024 | Buy Now | 112.77% | Wells Fargo | Derek Archila | $29 → $9 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 06/18/2024 | Buy Now | 136.41% | Stifel | Bradley Canino | $32 → $10 | Maintains | Buy | Get Alert |
| 06/18/2024 | Buy Now | 372.81% | HC Wainwright & Co. | Andrew Fein | $40 → $20 | Maintains | Buy | Get Alert |
| 06/18/2024 | Buy Now | 491.02% | Oppenheimer | Matthew Biegler | $50 → $25 | Maintains | Outperform | Get Alert |
| 06/18/2024 | Buy Now | 89.13% | Morgan Stanley | Matthew Harrison | $38 → $8 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 05/08/2024 | Buy Now | 845.63% | HC Wainwright & Co. | Andrew Fein | $46 → $40 | Maintains | Buy | Get Alert |
| 05/08/2024 | Buy Now | 656.5% | Stifel | Bradley Canino | $36 → $32 | Maintains | Buy | Get Alert |
| 02/28/2024 | Buy Now | 987.47% | HC Wainwright & Co. | Andrew Fein | → $46 | Reiterates | Buy → Buy | Get Alert |
| 02/28/2024 | Buy Now | 254.61% | Wedbush | Robert Driscoll | $12 → $15 | Maintains | Neutral | Get Alert |
| 11/08/2023 | Buy Now | 183.69% | Wedbush | Robert Driscoll | $38 → $12 | Downgrade | Outperform → Neutral | Get Alert |
| 11/07/2023 | Buy Now | 751.06% | Stifel | Bradley Canino | $44 → $36 | Maintains | Buy | Get Alert |
| 11/07/2023 | Buy Now | 798.35% | Morgan Stanley | Matthew Harrison | $55 → $38 | Maintains | Overweight | Get Alert |
| 11/07/2023 | Buy Now | 987.47% | HC Wainwright & Co. | Andrew Fein | $55 → $46 | Maintains | Buy | Get Alert |
| 08/10/2023 | Buy Now | 1082.03% | Wells Fargo | Derek Archila | $51 → $50 | Maintains | Overweight | Get Alert |
| 08/10/2023 | Buy Now | 798.35% | Wedbush | Robert Driscoll | → $38 | Reiterates | Outperform → Outperform | Get Alert |
| 08/10/2023 | Buy Now | 1200.24% | HC Wainwright & Co. | Andrew Fein | → $55 | Reiterates | Buy → Buy | Get Alert |
| 06/07/2023 | Buy Now | 798.35% | Wedbush | Robert Driscoll | → $38 | Reiterates | Outperform → Outperform | Get Alert |
| 06/07/2023 | Buy Now | 1082.03% | Stifel | Bradley Canino | $45 → $50 | Maintains | Buy | Get Alert |
| 06/02/2023 | Buy Now | 963.83% | Stifel | Bradley Canino | $45 → $45 | Maintains | Buy | Get Alert |
| 05/29/2023 | Buy Now | 963.83% | Stifel | Bradley Canino | $45 → $45 | Maintains | Buy | Get Alert |
| 05/26/2023 | Buy Now | 1082.03% | Oppenheimer | Matthew Biegler | → $50 | Reiterates | Outperform → Outperform | Get Alert |
| 05/26/2023 | Buy Now | 798.35% | Wedbush | Robert Driscoll | $31 → $38 | Maintains | Outperform | Get Alert |
| 05/26/2023 | Buy Now | 1200.24% | HC Wainwright & Co. | Andrew Fein | → $55 | Reiterates | Buy → Buy | Get Alert |
| 05/23/2023 | Buy Now | 963.83% | Stifel | Bradley Canino | $45 → $45 | Maintains | Buy | Get Alert |
| 05/19/2023 | Buy Now | 1554.85% | Jefferies | Biren Amin | $120 → $70 | Maintains | Buy | Get Alert |
| 05/15/2023 | Buy Now | 963.83% | Stifel | Bradley Canino | $45 → $45 | Maintains | Buy | Get Alert |
| 05/11/2023 | Buy Now | 963.83% | Stifel | Bradley Canino | $46 → $45 | Maintains | Buy | Get Alert |
| 05/11/2023 | Buy Now | 1200.24% | HC Wainwright & Co. | Andrew Fein | → $55 | Reiterates | Buy → Buy | Get Alert |
| 05/11/2023 | Buy Now | 1082.03% | Oppenheimer | Matthew Biegler | → $50 | Reiterates | Outperform → Outperform | Get Alert |
| 03/15/2023 | Buy Now | 987.47% | Stifel | Bradley Canino | $55 → $46 | Maintains | Buy | Get Alert |
| 03/02/2023 | Buy Now | 1200.24% | HC Wainwright & Co. | Andrew Fein | → $55 | Reiterates | → Buy | Get Alert |
| 03/01/2023 | Buy Now | 1200.24% | Stifel | Bradley Canino | $58 → $55 | Maintains | Buy | Get Alert |
| 11/14/2022 | Buy Now | 656.5% | Wedbush | Robert Driscoll | $51 → $32 | Maintains | Outperform | Get Alert |
| 11/11/2022 | Buy Now | 1200.24% | Morgan Stanley | Matthew Harrison | $60 → $55 | Maintains | Overweight | Get Alert |
| 11/11/2022 | Buy Now | 561.94% | Guggenheim | Michael Schmidt | $55 → $28 | Maintains | Buy | Get Alert |
| 11/10/2022 | Buy Now | 1082.03% | Oppenheimer | Matthew Biegler | $80 → $50 | Maintains | Outperform | Get Alert |
| 11/10/2022 | Buy Now | 538.3% | SVB Leerink | Andrew Berens | $42 → $27 | Maintains | Outperform | Get Alert |
| 11/09/2022 | Buy Now | 1271.16% | Stifel | Bradley Canino | $70 → $58 | Maintains | Buy | Get Alert |
| 08/11/2022 | Buy Now | 1318.44% | Morgan Stanley | Matthew Harrison | $95 → $60 | Maintains | Overweight | Get Alert |
| 08/10/2022 | Buy Now | 892.91% | SVB Leerink | Andrew Berens | $67 → $42 | Maintains | Outperform | Get Alert |
| 08/10/2022 | Buy Now | 1200.24% | HC Wainwright & Co. | Andrew Fein | $120 → $55 | Maintains | Buy | Get Alert |
| 07/29/2022 | Buy Now | 1554.85% | Stifel | Bradley Canino | $72 → $70 | Maintains | Buy | Get Alert |
| 07/12/2022 | Buy Now | — | Cowen & Co. | Tyler Van Buren | — | Initiates | → Outperform | Get Alert |
| 05/05/2022 | Buy Now | 1602.13% | Stifel | Bradley Canino | $74 → $72 | Maintains | Buy | Get Alert |
| 04/12/2022 | Buy Now | 1909.46% | Oppenheimer | Matthew Biegler | $100 → $85 | Maintains | Outperform | Get Alert |
| 04/12/2022 | Buy Now | 1483.92% | SVB Leerink | Andrew Berens | $78 → $67 | Maintains | Outperform | Get Alert |
| 04/11/2022 | Buy Now | 1649.41% | Stifel | Bradley Canino | $94 → $74 | Maintains | Buy | Get Alert |
| 04/06/2022 | Buy Now | 1483.92% | Wells Fargo | Derek Archila | → $67 | Initiates | → Overweight | Get Alert |
| 01/20/2022 | Buy Now | 2122.22% | Stifel | Bradley Canino | $88 → $94 | Maintains | Buy | Get Alert |
| 12/17/2021 | Buy Now | 2193.14% | SVB Leerink | Andrew Berens | — | Maintains | Outperform | Get Alert |
| 12/10/2021 | Buy Now | 2004.02% | SVB Leerink | Andrew Berens | — | Maintains | Outperform | Get Alert |
| 11/11/2021 | Buy Now | 2736.88% | HC Wainwright & Co. | Andrew Fein | — | Maintains | Buy | Get Alert |
| 10/27/2021 | Buy Now | 2004.02% | Wedbush | Robert Driscoll | $65 → $89 | Maintains | Outperform | Get Alert |
| 09/30/2021 | Buy Now | 1885.82% | Stifel | Bradley Canino | — | Initiates | → Buy | Get Alert |
| 09/29/2021 | Buy Now | 2027.66% | Oppenheimer | Matthew Biegler | — | Initiates | → Outperform | Get Alert |
FAQ
What is the target price for Zentalis Pharma (ZNTL) stock?
The latest price target for Zentalis Pharma (NASDAQ:ZNTL) was reported by UBS on June 20, 2024. The analyst firm set a price target for $5.00 expecting ZNTL to rise to within 12 months (a possible 18.20% upside). 17 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Zentalis Pharma (ZNTL)?
The latest analyst rating for Zentalis Pharma (NASDAQ:ZNTL) was provided by UBS, and Zentalis Pharma downgraded their neutral rating.
When was the last upgrade for Zentalis Pharma (ZNTL)?
There is no last upgrade for Zentalis Pharma
When was the last downgrade for Zentalis Pharma (ZNTL)?
The last downgrade for Zentalis Pharmaceuticals Inc happened on June 20, 2024 when UBS changed their price target from $28 to $5 for Zentalis Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for Zentalis Pharma (ZNTL)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Zentalis Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Zentalis Pharma was filed on June 20, 2024 so you should expect the next rating to be made available sometime around June 20, 2025.
Is the Analyst Rating Zentalis Pharma (ZNTL) correct?
While ratings are subjective and will change, the latest Zentalis Pharma (ZNTL) rating was a downgraded with a price target of $28.00 to $5.00. The current price Zentalis Pharma (ZNTL) is trading at is $4.23, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.